Researchers at the Council of Scientific and Industrial Research’s Institute of Genomics and Integrative Biology (CSIR-IGIB) in New Delhi have initiated Phase 1 human trials for BIRSA 101, an indigenous CRISPR gene therapy designed to treat sickle cell disease. The experimental treatment aims to provide a definitive genetic correction at a fraction of the $2.2 million cost associated with currently approved therapies like Casgevy, according to a report published earlier this week by India Today.
Sickle cell disease stems from a single genetic mutation, a solitary misprint in a three-billion-letter instruction manual, that causes red blood cells to become rigid, leading to vascular blockages, excruciating pain crises, and severe organ damage over time. To address this molecular error, BIRSA 101 utilizes a custom-engineered protein called enFnCas9, which acts as highly specific molecular scissors to locate and repair the precise DNA defect within a patient’s blood-forming stem cells.
Unlike the globally recognized Casgevy treatment, which relies on a widely available SpCas9 protein sourced from a common bacterium to reactivate a backup gene for fetal hemoglobin, the Indian therapy directly corrects the root genetic defect responsible for the cellular deformation. Dr. Souvik Maiti, co-inventor of the therapy alongside Debojyoti Chakraborty, noted that simply elevating fetal hemoglobin is suboptimal for Indian populations, who often naturally possess higher baseline levels of the protein compared to Western cohorts.
To manufacture the therapy at scale and ensure domestic availability, CSIR-IGIB has partnered with the Serum Institute of India, a collaboration intended to bring the projected cost down to roughly 50 lakh rupees per patient. The rigorous treatment protocol requires extracting stem cells from the patient’s spongy bone marrow tissue, performing the targeted genetic edit in a specialized laboratory, and reinfusing the corrected cells to establish a healthy, self-replicating blood supply.
If the corrected cells successfully settle into the bone marrow through a process known as engraftment, they can theoretically produce healthy, properly shaped red blood cells for the remainder of the patient’s life. This indigenous approach bypasses the limitations of therapies that merely manage symptoms, offering a targeted molecular intervention that addresses the exact biological mechanism of the inherited blood disorder.
The primary clinical hurdle for any CRISPR application remains the persistent risk of off-target editing, where the enzyme inadvertently alters unintended genomic sites and potentially triggers dangerous secondary mutations elsewhere in the DNA. Laboratory tests indicate that the custom enFnCas9 enzyme possesses an inherent ability to detect even a single DNA mismatch, avoiding incorrect binding sites with significantly greater reliability than conventional CRISPR tools.
“Highly sensitive genome-wide assays, which are detailed laboratory tests that examine the entire genetic code for errors, showed up to 1,000-fold fewer off-target events compared to conventional CRISPR tools,” Dr. Maiti said. “Taken together, these results give us strong confidence that BIRSA 101 edits only the intended DNA site with very high precision.”
This enhanced safety profile and dramatic cost reduction are particularly critical for patients in the heavily affected tribal belts of Jharkhand, Chhattisgarh, Madhya Pradesh, and Odisha, where access to continuous medical management is severely limited. A successful, one-time genetic intervention would eliminate the need for lifelong symptomatic care, fundamentally altering the clinical trajectory for regional populations bearing one of the heaviest global burdens of the disease.
As Phase 1 human trials progress in clinical settings, investigators will closely monitor patient engraftment rates to verify that the edited stem cells successfully multiply without triggering adverse immune responses. The medical community is awaiting these early outcome reports, which will provide the first real-world validation of the enFnCas9 protein’s efficacy outside of controlled laboratory environments.
While the initial genome-wide binding studies demonstrate high precision, extensive long-term clinical follow-up will be required to confirm whether BIRSA 101 can definitively deliver a permanent cure. If the trial data aligns with the preclinical models, the therapy could establish a new global paradigm for developing affordable, highly specific genetic medicines tailored to regional population genetics.
